Conditional transgenic models of BRCA1 mutant breast cancers have not been used widely in preclinical trials except for the study of K14-Cre; BRCA1fl/fl mouse in testing the efficacy of Olaparib43 and Topotecan44, wherein BRCA1 5-14 exon floxed animals were used. Here, KRT14 is linked to breast cancer.